OTLKW
Income statement / Annual
Last year (2021), Outlook Therapeutics, Inc. - Se's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2021, Outlook Therapeutics, Inc. - Se's net income was -$53.16 M.
See Outlook Therapeutics, Inc. - Se’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
09/30/2014 |
| Operating Revenue |
$0.00
|
$36.84 B
|
$8.15 M
|
$3.81 M
|
$2.98 M
|
$5.22 M
|
$5.22 M
|
$9.05 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$36.84 B |
$8.15 M |
$3.81 M |
$2.98 M |
$5.22 M |
$5.22 M |
$9.05 M |
| Gross Profit Ratio |
0 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$38.96 M
|
$0.00
|
$23.81 M
|
$23.81 M
|
$32.76 M
|
$38.88 M
|
$38.88 M
|
$14.12 M
|
| General & Administrative
Expenses |
$12.77 M
|
$9.97 B
|
$9.37 M
|
$15.88 M
|
$21.56 M
|
$12.91 M
|
$12.91 M
|
$7.32 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.77 M
|
$9.97 B
|
$9.37 M
|
$15.88 M
|
$21.56 M
|
$12.91 M
|
$12.91 M
|
$7.32 M
|
| Other Expenses |
$0.00 |
$0.00 |
$11.27 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$51.73 M |
$9.97 B |
$44.45 M |
$39.69 M |
$54.33 M |
$51.78 M |
$51.78 M |
$21.44 M |
| Cost And Expenses |
$51.73 M |
$9.97 B |
$44.45 M |
$39.69 M |
$54.33 M |
$51.78 M |
$51.78 M |
$21.44 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$936,127.00 |
-$1.76 B |
$3.47 M |
$5.63 M |
$1.85 M |
$2.30 M |
$2.30 M |
$901,052.00 |
| Depreciation &
Amortization |
$262,140.00
|
$554,069.00
|
$3.36 M
|
$3.05 M
|
$2.69 M
|
$2.39 M
|
$1.82 M
|
$878,477.00
|
| EBITDA |
-$51.97 M
|
-$37.00 B
|
-$31.11 M
|
-$29.67 M
|
-$48.66 M
|
-$42.89 M
|
-$43.46 M
|
-$11.51 M
|
| EBITDA Ratio |
0 |
-1 |
-3.82 |
-7.78 |
-16.33 |
-8.22 |
-8.33 |
-1.27 |
| Operating Income Ratio
|
0
|
-0
|
-4.46
|
-7.78
|
-12.04
|
-9.92
|
-8.92
|
-1.37
|
| Total Other
Income/Expenses Net |
-$1.43 M
|
-$38.47 B
|
-$1.64 M
|
-$8.70 M
|
-$17.32 M
|
$4.17 M
|
-$2.30 M
|
-$901,052.00
|
| Income Before Tax |
-$53.16 M |
-$38.51 B |
-$37.93 M |
-$38.35 M |
-$53.20 M |
-$47.58 M |
-$48.86 M |
-$13.29 M |
| Income Before Tax Ratio
|
0
|
-1.05
|
-4.66
|
-10.06
|
-17.85
|
-9.12
|
-9.36
|
-1.47
|
| Income Tax Expense |
-$498,486.00 |
-$40.23 B |
-$3.41 M |
$501,500.00 |
$103,000.00 |
-$190,111.00 |
-$190,111.00 |
$439,018.00 |
| Net Income |
-$53.16 M |
-$35.24 B |
-$34.52 M |
-$38.85 M |
-$53.30 M |
-$47.39 M |
-$47.39 M |
-$13.73 M |
| Net Income Ratio |
0 |
-0.96 |
-4.24 |
-10.19 |
-17.89 |
-9.08 |
-9.08 |
-1.52 |
| EPS |
-0.95 |
-628.28 |
-1.9 |
-1.62 |
-3.1 |
-4.86 |
-4.86 |
-1.41 |
| EPS Diluted |
-0.95 |
-628.28 |
-1.9 |
-1.62 |
-3.1 |
-4.86 |
-4.86 |
-1.41 |
| Weighted Average Shares
Out |
$56.09 M
|
$56.09 M
|
$18.19 M
|
$24.04 M
|
$17.21 M
|
$9.75 M
|
$9.75 M
|
$9.75 M
|
| Weighted Average Shares
Out Diluted |
$56.09 M
|
$56.09 M
|
$18.19 M
|
$24.04 M
|
$17.21 M
|
$9.75 M
|
$9.75 M
|
$9.75 M
|
| Link |
|
|
|
|
|
|
|
|
